Annual Report 2007 - Novo Nordisk

Pipeline Overview
Therapeutic area
Compound/product
Description
Diabetes care
Insulin
GLP-1
(Glucagon-Like Peptide-1)
Oral
NovoMix ® 50/70
NN5401
NN1250
Liraglutide
Liraglutide
Once-weekly GLP-1
PrandiMet
Premixed formulations of the rapid-acting modern insulin, insulin aspart. Provide a
combined rapid- and intermediate-acting insulin effect at the ratio 50/50 or 70/30.
A next-generation modern insulin.
A next-generation modern insulin.
A once-daily analogue of human GLP-1 stimulating the release of insulin only when
glucose levels become too high, and inducing weight loss.
A once-daily analogue of human GLP-1 stimulating the release of insulin only when
glucose levels become too high, and inducing weight loss.
A once-weekly analogue of human GLP-1.
A single tablet formulation combining the short-acting insulin secretagogue repaglinide
with an insulin-sensitising agent, metformin.
Biopharmaceuticals
Haemophilia
Haemostasis
Growth disorders
Hormone replacement therapy
Oncology
rFVIIa
Temperature stable
rFVIIa
Short-acting analogue
rFVIIa
Long-acting analogue
rFVIIa
Subcutaneous
NovoSeven ®
Novo Nordisk’s recombinant
blood clotting factor VIIa
rFXIII
Norditropin ®
Long-acting
human growth hormone
Vagifem ®
low dose
Activelle ®
low dose
IL-21
A temperature-stable recombinant factor VIIa.
A single-dose, short-acting rFVIIa analogue, a next-generation successor to NovoSeven ® .
A long-acting rFVIIa analogue, a next-generation molecule targeting prophylactic
therapy.
A subcutaneous formulation of rFVIIa for the treatment of haemophilia patients
with inhibitors.
The efficacy and safety of NovoSeven ® is tested on severe bleeding in trauma patients.
The efficacy and safety of NovoSeven ® is tested in spinal surgery patients.
The efficacy and safety of NovoSeven ® is tested in cardiac surgery patients.
A recombinant blood clotting factor XIII.
The efficacy of Novo Nordisk’s Norditropin ® in reducing mortality is tested in
adult patients in chronic dialysis treatment.
A long-acting human growth hormone.
A low-dose product for vaginal application intended for effective relief of symptoms
associated with vaginal dryness.
A low-dose continuous-combined product.
Interleukin 21 is an immuno-stimulatory protein that helps the immune system
attack tumour cells.
Anti-KIR
A first-in-class therapeutic antibody that stimulates the body’s own immune system to
kill cancer cells.
16 Novo Nordisk Annual Report 2007